
87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known
Publication
, Conference
Tarhini, A; Tan, AC; Naqa, IE; Lee, S; Stephen Hodi, F; Butterfield, L; LaFramboise, W; Storkus, W; Conejo-Garcia, J; Hwu, P; Streicher, H ...
Published in: Journal for ImmunoTherapy of Cancer
November 2021
Duke Scholars
Published In
Journal for ImmunoTherapy of Cancer
DOI
EISSN
2051-1426
Publication Date
November 2021
Volume
9
Issue
Suppl 2
Start / End Page
A95 / A95
Publisher
BMJ
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Tarhini, A., Tan, A. C., Naqa, I. E., Lee, S., Stephen Hodi, F., Butterfield, L., … Kirkwood, J. (2021). 87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known. In Journal for ImmunoTherapy of Cancer (Vol. 9, pp. A95–A95). BMJ. https://doi.org/10.1136/jitc-2021-sitc2021.087
Tarhini, Ahmad, Aik Choon Tan, Issam El Naqa, Sandra Lee, F. Stephen Hodi, Lisa Butterfield, William LaFramboise, et al. “87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known.” In Journal for ImmunoTherapy of Cancer, 9:A95–A95. BMJ, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.087.
Tarhini A, Tan AC, Naqa IE, Lee S, Stephen Hodi F, Butterfield L, et al. 87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known. In: Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A95–A95.
Tarhini, Ahmad, et al. “87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known.” Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, BMJ, 2021, pp. A95–A95. Crossref, doi:10.1136/jitc-2021-sitc2021.087.
Tarhini A, Tan AC, Naqa IE, Lee S, Stephen Hodi F, Butterfield L, LaFramboise W, Storkus W, Conejo-Garcia J, Hwu P, Streicher H, Sondak V, Kirkwood J. 87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known. Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A95–A95.

Published In
Journal for ImmunoTherapy of Cancer
DOI
EISSN
2051-1426
Publication Date
November 2021
Volume
9
Issue
Suppl 2
Start / End Page
A95 / A95
Publisher
BMJ
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology